ArticlePLoS genetics2013
Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis.
Article in PLoS genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 93 citations in OpenAlex.
- Overexpression of Rtl1 via synonymous mutation silencing miRNA target site drives skeletal muscle hypertrophy and inflammation in mice.BMC biology · 2026Article
- Article
- Copy-number dosage regulates telomere maintenance and disease-associated pathways in neuroblastoma.iScience · 2024Article
- Placenta: an old organ with new functions.Frontiers in immunology · 2024Review
- Understanding cancer drug resistance withiScience · 2023Article
- Discovery of a novel marker for human granulocytes and tissue macrophages: RTL1 revisited.Cell and tissue research · 2023Article
- Article
- Roles of retrovirus-derivedFrontiers in cell and developmental biology · 2023Review
- A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma.Cell & bioscience · 2022Article
- Deletion ofInternational journal of molecular sciences · 2022Article
- Evaluating the state of the science for adeno-associated virus integration: An integrated perspective.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Cellular origins of regenerating liver and hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2022Review
- Pluripotency Stemness and Cancer: More Questions than Answers.Advances in experimental medicine and biology · 2022Article
- Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers.Genome research · 2022Article
- Temporal Proteomic Profiling of SH-SY5Y Differentiation with Retinoic Acid Using FAIMS and Real-Time Searching.Journal of proteome research · 2021Article
- The Role of Long Non-coding RNAs in Human Imprinting Disorders: Prospective Therapeutic Targets.Frontiers in cell and developmental biology · 2021Review
- Identification of novel prognostic markers of survival time in high-risk neuroblastoma using gene expression profiles.Oncotarget · 2020Article
- The mammalian LINC complex component SUN1 regulates muscle regeneration by modulating drosha activity.eLife · 2019Article
- Retrotransposon gag-like 1 (RTL1) and the molecular evolution of self-targeting imprinted microRNAs.Biology direct · 2019Article
- HBx-K130M/V131I Promotes Liver Cancer in Transgenic Mice via AKT/FOXO1 Signaling Pathway and Arachidonic Acid Metabolism.Molecular cancer research : MCR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
We previously utilized a Sleeping Beauty (SB) transposon mutagenesis screen to discover novel drivers of HCC. This approach identified recurrent mutations within the Dlk1-Dio3 imprinted domain, indicating that alteration of one or more elements within the domain provides a selective advantage to cells during the process of hepatocarcinogenesis. For the current study, we performed transcriptome and small RNA sequencing to profile gene expression in SB-induced HCCs in an attempt to clarify the genetic element(s) contributing to tumorigenesis. We identified strong induction of Retrotransposon-like 1 (Rtl1) expression as the only consistent alteration detected in all SB-induced tumors with Dlk1-Dio3 integrations, suggesting that Rtl1 activation serves as a driver of HCC. While previous studies have identified correlations between disrupted expression of multiple Dlk1-Dio3 domain members and HCC, we show here that direct modulation of a single domain member, Rtl1, can promote hepatocarcinogenesis in vivo. Overexpression of Rtl1 in the livers of adult mice using a hydrodynamic gene delivery technique resulted in highly penetrant (86%) tumor formation. Additionally, we detected overexpression of RTL1 in 30% of analyzed human HCC samples, indicating the potential relevance of this locus as a therapeutic target for patients. The Rtl1 locus is evolutionarily derived from the domestication of a retrotransposon. In addition to identifying Rtl1 as a novel driver of HCC, our study represents one of the first direct in vivo demonstrations of a role for such a co-opted genetic element in promoting carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.